ReviewPakistan journal of medical sciences2026
Insulinoma-associated Protein-1 as a Biomarker for Diagnosis of Small Cell Lung Cancer: A Meta-analysis.
Review in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Conventional pathological examination can diagnose small cell lung cancer (SCLC) relying on the combined use of multiple immunohistochemical markers, and the diagnostic accuracy still does not meet clinical needs. In recent years, insulinoma-associated protein 1 (INSM1) has gradually demonstrated its value in identifying SCLC in surgical and biopsy specimens of lung tissue. Therefore, we aimed to evaluate the diagnostic utility of INSM1 as an immunohistochemical marker in accelerating and simplifying the diagnosis of SCLC. Methodology: PubMed, Embase and Web of Science databases were searched to retrieve literature. A meta-analysis was performed with Stata software (Stata 18.0). A random-effects model was used and subgroup analysis was carried out to identify possible sources of heterogeneity. Results: The initial search identified 257 articles. According to the inclusion criteria, 1523 patients from 10 studies were included in this meta-analysis. The pooled sensitivity and specificity of INSM1 immunohistochemistry for the diagnosis of SCLC were 0.93 (95% CI: 0.89 - 0.96) and 0.96 (95% CI: 0.92 - 0.98), respectively. The corresponding positive likelihood ratio (PLR) was 20.84 (95% CI: 11.64 - 37.32), and the negative likelihood ratio (NLR) was 0.07 (95% CI: 0.04 - 0.12). The area under the summary receiver operating characteristic (SROC) curve was 0.98 (95% CI: 0.97 - 0.99). Conclusions: INSM1 is a relatively promising and reliable immunohistochemical biomarker for the diagnosis of SCLC, with high sensitivity and specificity. In the future, INSM1 may be widely applied in the diagnosis of lung malignancies to improve the accuracy of pathological diagnosis for SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.